JMP Securities Reiterates Market Outperform on Elevation Oncology, Maintains $7 Price Target
Portfolio Pulse from Benzinga Newsdesk
JMP Securities analyst Silvan Tuerkcan reiterated a Market Outperform rating on Elevation Oncology (NASDAQ:ELEV) and maintained a $7 price target.
March 07, 2024 | 3:04 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
JMP Securities analyst Silvan Tuerkcan reiterated a Market Outperform rating on Elevation Oncology and maintained a $7 price target.
The reiteration of a Market Outperform rating and maintenance of a $7 price target by JMP Securities indicates a strong positive outlook for Elevation Oncology. This analyst endorsement can lead to increased investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100